Author:
Søndergaard Jonas Nørskov,van Heeringen Simon J.,Looman Maaike W. G.,Tang Chunling,Triantis Vassilis,Louche Pauline,Janssen-Megens Eva M.,Sieuwerts Anieta M.,Martens John W. M.,Logie Colin,Stunnenberg Hendrik G.,Ansems Marleen,Adema Gosse J.
Subject
Immunology,Immunology and Allergy
Reference60 articles.
1. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013
2. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma;Weber;J Clin Oncol,2013
3. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab;Yuan;Proc Natl Acad Sci U S A,2011
4. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010
5. Immunity, inflammation, and cancer;Grivennikov;Cell,2010
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献